Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 10/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.68 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904820 | 0.90 | CSF1R (0.73) | CSF1RKCNH2SCN5AMEN1KMT2A | |
| SCHEMBL2911029 | 0.89 | CSF1R (0.84) | CSF1RKCNH2SCN5AMEN1KMT2A | |
| SCHEMBL2907318 | 0.88 | KCNH2 (0.58) | CSF1RKCNH2SCN5AMEN1KMT2A | |
| SCHEMBL2909944 | 0.88 | CSF1R (0.78) | CSF1RKCNH2SCN5AMEN1KMT2A | |
| SCHEMBL2904648 | 0.87 | CSF1R (0.79) | CSF1RKCNH2SCN5AMEN1KMT2A | |
| SCHEMBL2905342 | 0.86 | KCNH2 (0.84) | CSF1RKCNH2SCN5AMEN1KMT2A | |
| SCHEMBL2904098 | 0.85 | CSF1R (0.77) | CSF1RKCNH2SCN5AMEN1KMT2A | |
| SCHEMBL2911651 | 0.85 | CSF1R (0.72) | CSF1RKCNH2SCN5AMEN1KMT2A | |
| SCHEMBL2909206 | 0.84 | CSF1R (0.64) | CSF1RKCNH2SCN5AMEN1KMT2A | |
| SCHEMBL2911256 | 0.84 | KCNH2 (0.76) | CSF1RKCNH2SCN5AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | disclosed |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-2010496-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007119046-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | CSF1R 1/4885KCNH2 3655/4885SCN5A 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.